Company Filing History:
Years Active: 2003-2007
Title: The Innovations of Dimitri Govorko
Introduction
Dimitri Govorko is a notable inventor based in Herzlia, IL. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting mutant p53 proteins. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
Govorko's latest patents focus on a single chain antibody against mutant p53. This invention addresses the fact that more than 90% of mutations found in the p53 protein lead to a conformational change, exposing an epitope that is typically hidden within the hydrophobic core of the molecule. The disclosed single chain antibody (scFv) specifically recognizes this common mutant epitope in mutant p53, while not affecting the wild type p53. Additionally, the patents describe a DNA molecule encoding the scFv, pharmaceutical compositions that include the antibody, and methods of treatment utilizing these pharmaceutical compositions.
Career Highlights
Dimitri Govorko is affiliated with Tel Aviv University, where he continues to engage in groundbreaking research. His work has garnered attention for its potential impact on therapeutic strategies for cancer patients.
Collaborations
Govorko collaborates with esteemed colleagues such as Beka Solomon and Gerald Cohen, contributing to a dynamic research environment that fosters innovation.
Conclusion
Dimitri Govorko's contributions to the field of biotechnology, particularly through his patents on antibodies against mutant p53, highlight his role as a significant inventor. His work not only advances scientific understanding but also holds promise for future medical applications.